Plasmodium berghei: Lack of antimalarial activity of an analogue of folate precursor, 2,4-diamino-6-hydroxymethylpteridine in a mouse model

Experimental Parasitology

Volumn 120, Issue 3, 2008, Pages 286-289

  Muregi, Francis W ^a,b   Kino, Hideto ^a   Ishih, Akira ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

2,4 Diamino N10 methylpteroic acid (DAMPA); 2,4 diaminopteridines; 2,4 Diaminopteroic acid (DAPA); 4 Diamino 6 hydroxymethylpteridine (DAP); Aminopterin (AMP); Antimalarial antifolates; Chloroquine (CQ); Deoxyribonucleic acid (DNA); Deoxythymidine monophosphate (dTMP); Dihydrofolate reductase (EC 1.5.1.3) (DHFR); Dihydropteroate synthase (EC 2.5.1.15) (DHPS); Folate analogues; Methotrexate (MTX); Plasmodium berghei; Ribonucleic acid (RNA); Thymidylate synthase (EC 2.1.1.45) (TS)

Indexed keywords

2,4 DIAMINO 6 HYDROXYMETHYLPTERIDINE; AMINOPTERIN; ANTIMALARIAL AGENT; FOLIC ACID DERIVATIVE; FOLINIC ACID; METHOTREXATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; MALARIA; MALE; MICROBIAL GROWTH; MOUSE; NONHUMAN; PLASMODIUM BERGHEI; PRIORITY JOURNAL; SURVIVAL;

AMINOPTERIN; ANIMALS; ANTIMALARIALS; DISEASE MODELS, ANIMAL; FOLIC ACID ANTAGONISTS; MALARIA; MALE; METHOTREXATE; MICE; MICE, INBRED ICR; PARASITEMIA; PLASMODIUM BERGHEI; PTERIDINES; RANDOM ALLOCATION;

MAMMALIA; MUS; PLASMODIUM BERGHEI;

EID: 53049083866     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2008.08.006     Document Type: Article

References (19)

1. Carlton J.M., Angiuoli S.V., Suh B.B., Kooij T.W., Pertea M., Silva J.C., Ermolaeva M.D., Allen J.E., Selengut J.D., Koo H.L., Peterson J.D., Pop M., Kosack D.S., Shumway M.F., Bidwell S.L., Shallom S.J., van Aken S.E., Riedmuller S.B., Feldblyum T.V., Cho J.K., Quackenbush J., Sedegah M., Shoaibi A., Cummings L.M., Florens L., Yates J.R., Raine J.D., Sinden R.E., Harris M.A., Cunningham D.A., Preiser P.R., Bergman L.W., Vaidya A.B., van Lin L.H., Janse C.J., Waters A.P., Smith H.O., White O.R., Salzberg S.L., Venter J.C., Fraser C.M., Hoffman S.L., Gardner M.J., and Carucci D.J. Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii. Nature 419 (2002) 512-519
2. Cohen I.J. Prevention of high-dose-methotrexate neurotoxicity by adequate folinic acid rescue is possible even after central nervous system irradiation. Medical Hypotheses 68 (2007) 1147-1153
3. Cole P.D., Drachtman R.A., Smith A.K., Cate S., Larson R.A., Hawkins D.S., Holcenberg J., Kelly K., and Kamen B.A. Phase II trial of oral aminopterin for adults and children with refractory acute leukemia. Clinical Cancer Research 11 (2005) 8089-8096
4. Gessler M.C., Tanner M., Chollet J., Nkunya M.H.H., and Heinrick M. Tanzanian medicinal plants used traditionally for the treatment of malaria: in vivo antimalarial and in vitro cytotoxic activities. Phytotherapy Research 9 (1995) 504-508
5. Gómez Z.M., and Rathod P.K. Antimalarial activity of a combination of 5-fluoroorotate and uridine in mice. Antimicrobial Agents and Chemotherapy 34 (1990) 1371-1375
6. Hekmat-Nejad M., and Rathod P.K. Kinetics of Plasmodium falciparum thymidylate synthase: interactions with high-affinity metabolites of 5-fluoroorotate and D1694. Antimicrobial Agents and Chemotherapy 40 (1996) 1628-1632
7. Ishih A., Miyase T., and Terada M. Comparison of antimalarial activity of the alkaloidal fraction of Hydrangea macrophylla var Otaksa leaves with the hot-water extract in ICR mice infected with Plasmodium yoelii 17 XL. Phytotherapy Research 17 (2003) 633-639
8. ® or minocycline hydrochloride against blood-induced choloquine-resistant Plasmodium berghei NK65 infections. Tropical Medicine and Health 32 (2004) 15-19
9. McGuire J.J. Anticancer antifolates: current status and future directions. Current Pharmaceutical Design 9 (2003) 2593-2613
10. Nduati E., Hunt S., Kamau E.M., and Nzila A. 2,4-diaminopteridine-based compounds as precursors for de novo synthesis of antifolates: a novel class of antimalarials. Antimicrobial Agents and Chemotherapy 49 (2005) 3652-3657
11. Nduati E., Diriye A., Ommeh S., Mwai L., Kiara S., Masseno V., Kokwaro G., and Nzila A. Effect of folate derivatives on the activity of antifolate drugs used against malaria and cancer. Parasitology Research 102 (2008) 1227-1234
12. Nzila A., Ward S.A., Marsh K., Sims P.F.G., and Hyde J.E. Comparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapy. Trends in Parasitology 21 (2005) 292-298
13. Nzila A., Ward S.A., Marsh K., Sims P.F.G., and Hyde J.E. Comparative folate metabolism in humans and malaria parasites (part II): activities as yet untargeted or specific to Plasmodium. Trends in Parasitology 21 (2005) 334-339
14. Nzila A. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. Journal of Antimicrobial Chemotherapy 57 (2006) 1043-1054
15. Ommeh S., Nduati E., Mberu E., Kokwaro G., Marsh K., Rosowsky A., and Nzila A. In vitro activities of 2,4-diaminoquinazoline and 2,4-diaminopteridine derivatives against Plasmodium falciparum. Antimicrobial Agents and Chemotherapy 48 (2004) 3711-3714
16. Polshakov V.I. Dihydrofolate reductase: structural aspects of mechanisms of enzyme catalysis and inhibition. Russian Chemical Bulletin 50 (2001) 1733-1751
17. Rathod P.K., Khatri A., Hubbert T., and Milhous W.K. Selective activity of 5-fluoroorotic acid against Plasmodium falciparum in vitro. Antimicrobial Agents and Chemotherapy 33 (1989) 1090-1094
18. Rathod P.K., Leffers N.P., and Young R.D. Molecular targets of 5-fluoroorotate in the human malaria parasite, Plasmodium falciparum. Antimicrobial Agents and Chemotherapy 36 (1992) 704-711
19. Waters A.P. Orthology between the genomes of Plasmodium falciparum and rodent malaria parasites: possible practical applications. Philosophical transactions of the Royal Society of London 357 (2002) 55-63